Italia markets closed

DBV Technologies S.A. (0QAJ.IL)

IOB - IOB Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,3330+0,0030 (+0,23%)
Alla chiusura: 05:47PM GMT
Schermo intero
Chiusura precedente1,3300
Aperto1,3720
Denaro1,2850 x 0
Lettera1,3660 x 0
Min-Max giorno1,2910 - 1,3720
Intervallo di 52 settimane1,0990 - 4,1960
Volume6.405
Media Volume3.463
Capitalizzazione151,197M
Beta (5 anni mensile)1,15
Rapporto PE (ttm)N/D
EPS (ttm)-0,9300
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

    Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a

  • GlobeNewswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2023 96,253,553 Total gross of voting rights: 96,253,553 Total net* of voting rights: 96,076,898 * Net total = total number of voting rights attached to shares – shares

  • GlobeNewswire

    DBV Technologies to Participate in Upcoming Investor Conference

    Montrouge, France, September 5, 2023 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11th −13th in New York, NY. Daniel Tassé, Chief Executive Officer, will represent the company in a fireside chat session on Tuesday, September